Key Resolutions

Two special resolutions are proposed for shareholder approval through postal ballot:

Item No. 1: Revision in remuneration of Mr. Mohanraj Sanjeevi (DIN: 08420411)

  • Designation: Whole Time Director (Executive Director) and Chief Human Resources Officer (CHRO)
  • Current Term: January 1, 2026 to December 31, 2028 (approved by shareholders on March 6, 2026)
  • Effective Date of Revision: July 1, 2026
  • Proposed Remuneration Revision:
  • Fixed Remuneration: Increased from ₹85,00,000 to ₹95,00,000 per annum
  • Variable Pay: ₹15,00,000 per annum (50% individual performance, 50% company performance)
  • Long Term Incentive Plan (LTIP): New allocation of ₹40,00,000 aggregate cost during remaining tenure
  • 60% performance linked, 40% tenure linked
  • Payout schedule: July 2027 (37.5%/₹15,00,000), July 2028 (62.5%/₹25,00,000)
  • ESOP Details: 25,000 options granted under ESOP Plan 2024 at exercise price of ₹375 per share
  • Vesting schedule: November 2026 (5,000), November 2027 (7,500), November 2028 (12,500)
  • No options exercised as of date

Item No. 2: Revision in remuneration of Mr. Sandeep Shashikantha Rao (DIN: 10838251)

  • Designation: Managing Director and Chief Executive Officer (CEO)
  • Current Term: February 21, 2025 to February 20, 2028 (approved by shareholders on April 19, 2025)
  • Effective Date of Revision: July 1, 2026
  • Proposed Remuneration Revision:
  • Fixed Remuneration: Increased from ₹3,25,00,000 to ₹4,00,00,000 per annum
  • Variable Pay: Increased from ₹75,00,000 to ₹1,50,00,000 per annum (50% individual performance, 50% company performance)
  • Long Term Incentive Plan (LTIP): New allocation of ₹5,00,00,000 aggregate cost
  • 60% performance linked, 40% tenure linked
  • Payout schedule: December 2026 (15%/₹75,00,000), July 2027 (20%/₹1,00,00,000), July 2028 (25%/₹1,25,00,000), July 2029 (40%/₹2,00,00,000)
  • Tranches beyond February 2028 subject to reappointment
  • ESOP Details:
  • 200,000 options granted under ESOP Plan 2024 at exercise price of ₹375 per share
  • Vesting schedule: February 2026 (40,000), February 2027 (60,000), February 2028 (100,000)
  • 40,000 options exercised, 160,000 outstanding
  • Additional 100,000 options granted
  • Vesting schedule: October 2027 (20,000), October 2028 (30,000), October 2029 (50,000)

Voting Schedule

  • Cut-off Date: November 13, 2026
  • Dispatch Completion Date: November 17, 2026
  • E-voting Period: November 18, 2026 (9:00 AM IST) to December 17, 2026 (5:00 PM IST)
  • Result Declaration: On or before December 21, 2026

Rationale for Revision

The Nomination and Remuneration Committee and Board reviewed both executives' performance on October 16, 2026, and noted significant contributions including:

  • Strengthening human capital strategy and organizational transformation
  • Driving operational excellence and business performance improvements
  • Enhancing governance, risk management, and compliance frameworks
  • Leading key business development initiatives

Financial Context

The company reported inadequate profits in FY 2025-26 mainly due to:

  • Continued weakness in commodity Ibuprofen business
  • Global oversupply and pricing pressure in API market
  • Increased supply chain and logistics costs
  • Finance costs and depreciation

FY 2025-26 Financials (Standalone):

  • Total Revenue: ₹1,374.87 crore
  • Total Expense: ₹1,376.22 crore (excluding exceptional items)
  • Profit/(Loss) After Tax: (₹7.24 crore)

Minimum Remuneration Clause

In case of loss or inadequacy of profits, remuneration will be paid as minimum remuneration in compliance with Schedule V of Companies Act, 2013.

Scrutinizer Appointment

Mr. Preetham Hebbar (CoP No. 21431) of M/s. Preetham Hebbar & Co., Practicing Company Secretaries, appointed as scrutinizer.

E-voting Process

Remote e-voting facilitated by CDSL for all members as of cut-off date. Members can vote through:

  • Depository participants (for demat holders)
  • CDSL e-voting system (for physical shareholders and non-individual shareholders)